Bryce D. Carmine

HaemaLogiX Pty Ltd. is a biotech company located in Sydney, Australia. The Australian company has a wide range and depth of experience in antibody research, nonclinical & clinical development, manufacturing, and commercialization. The scientific advisory board members are internationally recognized experts in monoclonal antibody therapies and hematology. The company's current research and clinical trial partners are leaders in multiple myeloma and AL amyloidosis therapy. Founded in 2014, the company is researching immune-based treatments such as monoclonal antibodies, CAR T cell therapies, and bispecific antibodies to target unique antigens on malignant cells and improve the quality of life of patients suffering from blood cancers like multiple myeloma and other life-threatening diseases like AL amyloidosis. Bryce D. Carmine has been the CEO of the company since 2015.

Part of Eli Lilly & Co., Eli Lilly Japan KK is a Japanese company that manufactures and trades pharmaceutical products. The private company is based in Kobe, Japan.

Eli Lilly Australia Pty Ltd. manufactures and supplies pharmaceutical products. It develops medicines for diabetes, cancer, immunology, and pain. The company was founded in 1960 and is headquartered in West Ryde, Australia.

ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ.